← All trials
NCT05063149
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Apr 30, 2025
- Completion date
- Apr 30, 2026
- First posted
- Sep 30, 2021
- Last posted
- Sep 30, 2021
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Franciscus GasthuisLead sponsor
- Maastricht UniversityCollaborator
- Leiden UniversityCollaborator
- Franciscus GasthuisReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.